STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
State Street Corporation reports beneficial ownership of 4,995,259 shares of STERIS PLC, representing 5.1% of the class as of 03/31/2026. The filing states shared voting power of 3,198,310 shares and shared dispositive power of 4,992,076.
The Schedule 13G lists multiple State Street-related entities as holders and is signed by a senior company officer on 05/12/2026. The filing discloses ownership on behalf of clients and affiliated investment-adviser and trustee entities.
STERIS plc reported strong results for fiscal 2026 and raised its outlook. Revenue from continuing operations grew 9% to $5.94 billion, while constant currency organic revenue increased 7%. As reported diluted EPS from continuing operations rose to $7.93, and adjusted EPS increased to $10.17.
Growth was broad-based: Healthcare revenue reached $4.21 billion, AST $1.14 billion, and Life Sciences $588.8 million. Net income from continuing operations was $782.3 million, and free cash flow improved to $982.9 million on operating cash flow of $1.34 billion.
For fiscal 2027, STERIS expects reported revenue to grow 7–8% and constant currency organic revenue 6–7%. Adjusted EPS is projected between $11.10 and $11.30, up 9–11% from fiscal 2026. The Board also authorized a new $1 billion share repurchase program, and capital expenditures of about $375 million will include a new sterility assurance plant in Mentor, Ohio.
STERIS plc reported changes to its Board of Directors. Long-serving director Richard C. Breeden will retire and not stand for reelection at the 2026 Annual General Meeting, with the company noting his decision is not due to any disagreement over operations, policies or practices.
The Board increased its size from nine to ten members and appointed Pierre Boulud, CEO of bioMérieux, as a director effective May 5, 2026. He brings experience in in vitro diagnostics, biopharma and strategy roles. Boulud will receive a prorated fee of $76,989 for the 2025-26 Board term, paid in career restricted stock units under STERIS’s Non-Employee Director Compensation Program.
STERIS PLC ownership disclosure: Vanguard Capital Management reports beneficial ownership of 7,340,236 shares of common stock, representing 7.48% of the class. The filing states Vanguard has sole dispositive power over 7,340,236 shares and sole voting power over 973,858 shares. The statement describes holdings on behalf of Vanguard-managed vehicles and affiliates.
STERIS PLC ownership filing: Vanguard Portfolio Management reports beneficial ownership of 4,962,018 shares of Common Stock, representing 5.05% of the class. The filing states Vanguard exercises sole dispositive power over those shares and reports 11,978 shares of sole voting power. The disclosure describes holdings on behalf of Vanguard funds and managed accounts and is signed by the Head of Global Fund Administration.
STERIS plc amended its Transition Agreement with former Chief Financial Officer Michael J. Tokich to keep him on as a part-time senior financial advisor from April 1, 2026 through March 31, 2027, called the Extended Advisor Period.
During this time, his annual base salary will be reduced to $60,000, he may receive a discretionary cash bonus approved by the Compensation and Organization Development Committee, and he will no longer be eligible for the Company’s health, dental, life insurance, vacation, disability or other employee benefit plans. All other terms of the original Agreement remain in effect during the Extended Advisor Period.
STERIS PLC Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of common stock after an internal realignment on January 12, 2026. The filing explains certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
STERIS plc director Cynthia L. Feldmann exercised stock options and sold shares in a same‑day transaction. She exercised options for 3,098 ordinary shares through a derivative conversion, then acquired the same number of ordinary shares at a price of $152.32 per share. She subsequently sold 3,098 ordinary shares in an open‑market transaction at a weighted average price of $237.21 per share, leaving 705 ordinary shares held directly. In addition, 8,663 ordinary shares are held indirectly in a revocable trust for which Ms. Feldmann and her husband serve as trustees.
STERIS plc reported solid growth for the nine months ended December 31, 2025. Total revenues rose to $4,347.5 million from $3,979.0 million, with balanced increases in Healthcare, AST, and Life Sciences. Net income attributable to shareholders grew to $562.1 million, and diluted EPS from continuing operations increased to $5.69 from $4.68.
Gross profit reached $1,929.4 million, while operating income from continuing operations improved to $785.0 million, despite $5.1 million of acquisition and integration expenses and $3.0 million of restructuring costs. Cash flow from operating activities was strong at $1,006.0 million, supporting capital expenditures of $278.8 million and share repurchases of $161.2 million plus $180.0 million in dividends.
The balance sheet showed cash and cash equivalents of $423.7 million and total debt of $1,898.4 million, with shareholders’ equity rising to $7,154.5 million. The company completed the Dental segment sale (reported as discontinued operations) and continues to manage restructuring in its Healthcare surgical business in Europe and an ethylene oxide litigation settlement framework in Illinois, as well as ongoing IRS tax matters.